Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | GSR | P00390 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2159745 | 0.70 | IDO1 (0.33) | SMN1; SMN2ALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL3096746 | 0.70 | APAF1 (0.33) | SMN1; SMN2MAPK1ALDH1A1HPGDNPC1 | |
| SCHEMBL816040 | 0.70 | ALDH1A1 (0.31) | ALDH1A1NPC1RAB9AMEN1MAPT | |
| SCHEMBL15157006 | 0.65 | L3MBTL1 (0.35) | CYP2D6SMN1; SMN2ALDH1A1NPC1MEN1 | |
| SCHEMBL5737227 | 0.65 | MEN1 (0.33) | ALDH1A1MEN1LMNABLMKMT2A | |
| SCHEMBL1091565 | 0.65 | GPR84 (0.35) | LMNATSHR | |
| SCHEMBL8078829 | 0.64 | ALDH1A1 (0.36) | SMN1; SMN2ALDH1A1LMNAMAPTTSHR | |
| SCHEMBL7778902 | 0.64 | ALDH1A1 (0.41) | SMN1; SMN2MAPK1ALDH1A1HPGDNPC1 | |
| SCHEMBL20585044 | 0.64 | MAPT (0.43) | SMN1; SMN2MAPK1ALDH1A1HPGDNPC1 | |
| SCHEMBL30565769 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114181150-A | Pyrazole amide derivative, preparation method and application thereof | 沈阳万菱生物技术有限公司 | 2022-03-15 | — | — | CN | claimed |
| US-20160331725-A1 | USE OF COMPOUNDS THAT ARE ABLE TO INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASE STATES ASSOCIATED WITH A REDUCED IGF-1 SERUM LEVEL IN HUMANS AND ANIMALS | VEIJLEN N.V. | 2016-11-17 | — | — | US | claimed |
| EP-1441719-B1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-03-30 | — | — | EP | claimed |
| US-7803819-B2 | DPP IV inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2010-09-28 | — | — | US | claimed |
| US-20080194553-A1 | compounds that are capable of increasing the serum level of insulin-like growth factor 1 (IGF-1) for the preparation of a therapeutical composition,in the form of a food supplement, for the treatment of subjects suffering from serious fatigue and exhausting symptoms, burn-out and chronic fatigue syndrome | VEIJLEN N.V. (NL) | 2008-08-14 | — | — | US | claimed |
| US-20070259925-A1 | DPP IV INHIBITORS | BOEHRINGER MARKUS | 2007-11-08 | — | — | US | claimed |
| EP-1670444-A2 | USE OF INDOLEACETIC ACID DERIVATIVES WHICH INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASES | Veijlen N.V. (AN) | 2006-06-21 | — | — | EP | claimed |
| WO-2005039546-A2 | USE OF INDOLEACETIC ACID DERIVATIVES WHICH INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASES | VEIJLEN N.V. (AN) | 2005-05-06 | — | — | WO | claimed |
| US-20050096348-A1 | DPP IV inhibitors | BOEHRINGER MARKUS (CH) | 2005-05-05 | — | — | US | claimed |
| US-20030130281-A1 | DPP IV inhibitors | HOFFMAN-LA ROCHE INC. | 2003-07-10 | — | — | US | claimed |
| US-5654298-A | QUARTERNARY SALTS OF 4-AMINO-SUBSTITUTED PYRIDINES; MODULATORS OF THE SINOATRIAL NODE; CARDIOTONIC AND BRADYCARDIA AGENTS; | IMPERIAL CHEMICAL INDUSTRIES (GB) | 1997-08-05 | — | — | US | claimed |
| EP-0431856-B1 | Heterocyclic compounds | ZENECA LTD (GB) | 1995-07-12 | — | — | EP | claimed |
| EP-0422178-B1 | PYRIMIDINE DERIVATIVES | ZENECA LTD (GB) | 1994-10-05 | — | — | EP | claimed |
| US-5332737-A | Cardiovascular disorders | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-07-26 | — | — | US | claimed |
| EP-0453197-B1 | Amine derivatives | ICI PLC (GB) | 1994-06-15 | — | — | EP | claimed |
| US-5223505-A | PYRIMIDINE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-06-29 | — | — | US | claimed |
| EP-0453197-A1 | Amine derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-10-23 | — | — | EP | claimed |
| EP-0431856-A2 | Heterocyclic compounds | ZENECA LIMITED (GB) | 1991-06-12 | — | — | EP | claimed |
| EP-0422178-A1 | PYRIMIDINE DERIVATIVES. | ICI PLC (GB) | 1991-04-17 | — | — | EP | claimed |
| WO-1990012790-A1 | PYRIMIDINE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-11-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259925-A1 | DPP IV INHIBITORS | DPP4, DPP3, DPP7 | CYP1A2 555/4885CYP2D6 148/4885SMN1; SMN2 2529/4885 |
| US-20030130281-A1 | DPP IV inhibitors | DPP4, DPP3, DPP7 | CYP1A2 655/4885CYP2D6 271/4885SMN1; SMN2 1935/4885 |
| US-20050096348-A1 | DPP IV inhibitors | DPP4, DPP3, DPP7 | CYP1A2 555/4885CYP2D6 148/4885SMN1; SMN2 2529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.